Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer

Abdullah Evren Yetişir ¹, Semra Paydaş ², Mahmut Büyükşimşek ¹

⁰Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey.

Journal of Cancer Research and Therapeutics +

|

March 30, 2024

View abstract on PubMed

Summary

Neutrophil-lymphocyte ratios (dNLR, NLR), LMR, and PLR predict survival in EGFR-mutant NSCLC patients treated with erlotinib. NLR showed the best diagnostic performance for predicting overall survival and progression-free survival.

Area Of Science

Oncology
Medical Diagnostics

Background

Investigating prognostic markers in non-small cell lung cancer (NSCLC).
Focus on epidermal growth factor receptor (EGFR)-mutant NSCLC, a specific subtype.
Evaluating the role of inflammation-based ratios in cancer prognosis.

Purpose Of The Study

To assess the association between dNLR, NLR, LMR, and PLR and survival outcomes (OS, PFS).
To determine the predictive value of these ratios in EGFR-mutant NSCLC patients receiving erlotinib.

Main Methods

Retrospective analysis of 43 patients with EGFR-mutant metastatic NSCLC.
Calculation of dNLR, NLR, LMR, and PLR from baseline complete blood counts.
Analysis of pre- and post-treatment values to evaluate changes.

Main Results

NLR demonstrated the highest sensitivity (91.3%) in diagnostic testing.
All tested ratios (dNLR, NLR, LMR, PLR) were significant predictors of OS and PFS.
Delta dNLR and NLR were significant for OS, while delta NLR was significant for PFS.

Conclusions

dNLR, NLR, LMR, and PLR are significant predictors of survival in erlotinib-treated metastatic NSCLC.
NLR shows strong potential as a prognostic biomarker in this patient group.
Further research is needed to identify optimal targeted therapies for EGFR-mutant NSCLC.